173 related articles for article (PubMed ID: 31912332)
1. Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.
Nemoto K; Kawashiro S; Toh Y; Numasaki H; Tachimori Y; Uno T; Jingu K; Matsubara H
Esophagus; 2020 Apr; 17(2):122-126. PubMed ID: 31912332
[TBL] [Abstract][Full Text] [Related]
2. Current status of radiotherapy for patients with thoracic esophageal cancer in Japan, based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.
Toh Y; Numasaki H; Tachimori Y; Uno T; Jingu K; Nemoto K; Matsubara H
Esophagus; 2020 Jan; 17(1):25-32. PubMed ID: 31473871
[TBL] [Abstract][Full Text] [Related]
3. Chemoradiotherapy and radiotherapy alone in patients with esophageal cancer aged 80 years or older based on the Comprehensive Registry of Esophageal Cancer in Japan.
Jingu K; Numasaki H; Toh Y; Nemoto K; Uno T; Doki Y; Matsubara H
Esophagus; 2020 Jul; 17(3):223-229. PubMed ID: 32088786
[TBL] [Abstract][Full Text] [Related]
4. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
Suh YG; Lee IJ; Koom WS; Cha J; Lee JY; Kim SK; Lee CG
Jpn J Clin Oncol; 2014 Jun; 44(6):534-40. PubMed ID: 24771865
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
[TBL] [Abstract][Full Text] [Related]
7. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
8. Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy.
Kim HJ; Suh YG; Lee YC; Lee SK; Shin SK; Cho BC; Lee CG
Cancer Res Treat; 2017 Jul; 49(3):669-677. PubMed ID: 27737537
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
10. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience.
Wang S; Liao Z; Chen Y; Chang JY; Jeter M; Guerrero T; Ajani J; Phan A; Swisher S; Allen P; Cox JD; Komaki R
J Thorac Oncol; 2006 Mar; 1(3):252-9. PubMed ID: 17409865
[TBL] [Abstract][Full Text] [Related]
11. Radiation therapy for esophageal cancer in Japan: results of the Patterns of Care Study 1999-2001.
Kenjo M; Uno T; Murakami Y; Nagata Y; Oguchi M; Saito S; Numasaki H; Teshima T; Mitsumori M
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):357-63. PubMed ID: 19735863
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
[TBL] [Abstract][Full Text] [Related]
13. Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012.
Brower JV; Chen S; Bassetti MF; Yu M; Harari PM; Ritter MA; Baschnagel AM
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):985-993. PubMed ID: 27869098
[TBL] [Abstract][Full Text] [Related]
14. Process and preliminary outcome of a patterns-of-care study of esophageal cancer in Japan: patients treated with surgery and radiotherapy.
Gomi K; Oguchi M; Hirokawa Y; Kenjo M; Ogata T; Takahashi Y; Nakamura N; Yamashita T; Teshima T; Inoue T;
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):813-22. PubMed ID: 12788190
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
16. High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma.
Yorozu A; Dokiya T; Oki Y
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):271-5. PubMed ID: 10487545
[TBL] [Abstract][Full Text] [Related]
17. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG
Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788
[TBL] [Abstract][Full Text] [Related]
18. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
19. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
[TBL] [Abstract][Full Text] [Related]
20. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
